Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields (CORRECTED)
Author: Avi Kapoor | June 18, 2025 11:15am
Editor's Note: This story has been updated to correct the name of the Citigroup analyst responsible for the downgrade of Merck.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
UBS analyst Trung Huynh maintained a Neutral rating and increased the price target from $24 to $25 on April 30, 2025. This analyst has an accuracy rate of 71%.
Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 74%.
Recent News: Arvinas, Inc. (NASDAQ:ARVN) on June 6 announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer.
Benzinga Pro’s real-time newsfeed alerted to latest PFE news.
Citigroup analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 70%.
Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.
Recent News: The U.S. Food and Drug Administration (FDA) on Friday approved Merck's Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
Benzinga Pro's real-time newsfeed alerted to latest MRK news
UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $27 to $25 on May 9, 2025. This analyst has an accuracy rate of 71%.
Mizuho analyst Steven Valiquette maintained a Neutral rating and lowered the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 62%.
Recent News: On June 5, Dentsply Sirona priced an offering of $550 million of junior subordinated notes.
Benzinga Pro’s real-time newsfeed alerted to latest XRAY news
